

## CSIM Annual Meeting 2023 Evidence of Conflict of Financial Interest

### Planning Committee

Last Name	First Name	Declaration
<b>Arsenault</b>	Marie-Pier	Speaker Honoraria: Thrombosis Canada
<b>Cérat</b>	Stéphanie	Employed by: MUHC
<b>Chisick</b>	Laura	No conflicts to declare
<b>Echenberg</b>	Donald	No conflicts to declare
<b>Grand'Maison</b>	Sophie	Speaker honoraria: Servier
<b>Hendricks</b>	Amy	No conflicts to declare.
<b>Lambert</b>	Lynn	No conflicts to declare.
<b>Simard</b>	Camille	No conflicts to declare
<b>Savard-Heppell</b>	Jennifer	No conflicts to declare
<b>Srivaratharajah</b>	Kajenny	No conflicts to declare.
<b>Touchette</b>	Matthieu	No conflicts to declare

## Presenters

Last Name	First Name	Declaration
<b>Auguste</b>	Bourne	Speaker fees: Amgen, Baxter Healthcare
<b>Azelos</b>	Ilan	Honoraria for speaker fees, ad-board meetings, research support, preceptorship fees: Boehringer-Ingelheim, Jamp, Roche. BUILD grant: Boehringer-Ingelheim
<b>Balan</b>	Marko	Financial investments: Merck & Co
<b>Bessissow</b>	Amal	No conflicts to declare
<b>Bridges</b>	Eileen	Employed by: CMPA
<b>Bunce</b>	Paul	No conflicts to declare
<b>Cadrin-Tourigny</b>	Julia	Speaker honoraria: Bayer, BMS/Pfizer Advisory board: Lexeo, Tenaya
<b>Dayan</b>	Natalie	Honoraria for lectures: HTaq biomedical. Study funding: CIHR, FRQS, HSFC
<b>Douketis</b>	James	Honoraria: Pfizer, Leo Pharma Advisory Board Consultant: Servier, CytoSorb, Fresenius-Kabi Grant/Clinical Trial Funding: CIHR Non-Employee Consultant: Up-to-Date, Merck Manual
<b>Duceppe</b>	Emmanuelle	Research grants for investigator-initiated project: Roche Diagnostics, Abbott Laboratories
<b>Dyrda</b>	Katia	Speaker honoraria: Bayer, Servier, J&J
<b>Feilchenfeld</b>	Zachary	No conflicts to declare
<b>Gaudreau-Simard</b>	Mathilde	No conflicts to declare
<b>Godbout</b>	Krystelle	Speaker fees: AstraZeneca, Boehringer, Covis, GSK, Novartis, Valeo Advisory boards: AstraZeneca, Covis, GSK, Sanofi, TEVA, Valeo Co investigators in industry-sponsored clinical trials: AstraZeneca, Bellus, GSK, Regeneron, Sanofi, Valeo, Viatrix

<b>Guzman</b>	Juan	Medical Advisor: The Angel Project Co-Investigator: University of Calgary, Ottawa Hospital Research Institute  <b><i>This speaker intends to make therapeutic recommendations for medications that have not received regulatory approval.</i></b>
<b>Jaswal</b>	Gurpreet	No conflicts to declare
<b>Jayaraman</b>	Dev	No conflicts to declare
<b>Koolian</b>	Maral	No conflicts to declare
<b>Lamarre-Cliche</b>	Maxime	Member of Board: Société Québécoise d'Hypertension Artérielle
<b>Lamontagne</b>	François	Funded grants or clinical trials: 1) National Institute for Health and Care Research (65 Trial (JAMA. 2020 Mar 10;323(10):938-949)); 2) Lotte & John Hecht Memorial Foundation (N Engl J Med. 2022 Jun 23;386(25):2387-2398) Patents: Research work on automated dosing of vasopressor agents that was conducted under my supervision led to a discovery subject intellectual property protection (patent).
<b>Lanthier</b>	Luc	No conflicts to declare
<b>Lapointe-Shaw</b>	Lauren	Research funding: CIHR, PSI Foundation, University of Toronto Department of Medicine, the Toronto General Hospital RCIHR, PSI Foundation, Peter Gilgan Centre for Women's Cancers at Women's College Hospital, in partnership with the Canadian Cancer Society.
<b>Lavoie</b>	Hélène	No conflicts to declare
<b>Leroux</b>	Elizabeth	Advisory Board/Honoraria: Allergan/Abbvie, Aralez/Tribute/Miravo Pharmaceuticals, Eli Lilly, Lundbeck, Teva Neurosciences, Novartis Speaker Honoraria: Allergan/Abbvie, Aralez/Tribute/Miravo Pharmaceuticals, Eli Lilly, Lundbeck, McKesson Canada, MedScape, Teva Neurosciences, Novartis. Consultant Honoraria: Allergan/Abbvie, Eli Lilly, LinPharma, McKesson Canada, MedScape Paladin, Teva Neurosciences, Novartis
<b>Ly</b>	Khuê	No conflicts to declare

<b>Ma</b>	Irene	Honoraria: American College of Physicians, Canadian Society of Internal Medicine Executive member but do not receive payments: American Institute of Ultrasound in Medicine Governor but do not receive payments: Alberta Chapter for American College of Physicians Operating grant recipient for a research study: University of Calgary Office of Health & Medical Education Scholarship
<b>Makhzoum</b>	Jean-Paul	Presentation fees and consultation: Roche®, Otsuka®, GlaxoSmithKline®, AstraZeneca®, Sanofi® Attendance to advisory boards: Roche®, Otsuka®, GlaxoSmithKline®, Sanofi® Research grants: Health Canada, the Vasculitis Clinical Research Consortium (VCRC), Canadian Network for Research on Vasculitides (CanVasc), Janssen®, Novartis®  <b><i>This speaker intends to make therapeutic recommendations for medications that have not received regulatory approval.</i></b>
<b>Malhamé</b>	Isabelle	Research institution received grant funding for research projects related to women's health and nominated Principle Investigator: CIHR, Canadian Foundation for Women's Health, Kitty Carr Foundation
<b>McCulloch</b>	Sylvia	Advisory Boards or Speakers' Bureaus: ForUS therapeutics, Janssen, Pfizer, Sanofi
<b>Mielniczuk</b>	Lisa	Ad boards, speaker fees: Servier, Bayer, Novartis, Merck, BI, Astra Zeneca, Janssen <b><i>This speaker intends to make therapeutic recommendations for medications that have not received regulatory approval.</i></b>
<b>Mong</b>	Jon	No conflicts to declare. <b><i>This speaker intends to use trade names: Suboxone (Buprenorphine-Naloxone), Kadian (Sustained Release Oral Morphine)</i></b>
<b>Morin</b>	Marie-Philippe	Speaker honoraria: Novo Nordisk, Bausch-Health, Janssen, AstraZeneca, Lilly, Boehringer, Nestle, Mantra pharma, Takeda Advisory Board honoraria: Novo Nordisk, Rhythm, Bausch-Health, Janssen, AstraZeneca, Lilly, Boehringer, Nestle, Mantra pharma, Takeda  <b><i>This speaker intends to make therapeutic recommendations for medications that have not received regulatory approval.</i></b>
<b>Muccilli</b>	Alex	No conflicts to declare
<b>Raymond</b>	Jean-Marc	Speaker honoraria/consultant: Servier, Biosense Webster
<b>Saleh</b>	Ramy	No conflicts to declare

<b>Stoynova</b>	Valeria	Advisory Committee Stipend and Project Funding: Creating a Sustainable Canadian Healthcare System in a Climate Crisis (CASCADES) (NFP)
<b>Tang</b>	Brandon	Royalties for "Vancouver Notes for Internal Medicine" book: Brush Education Grant funding: Royal College of Physicians and Surgeons of Canada, PSI Foundation, and the University of Toronto Department of Medicine
<b>Thanassoulis</b>	George	Speaker bureau, advisory boards: Amgen, Sanofi, Novartis, HLS therapeutics, New Amsterdam, Silence Funding for participating in RCTs: Novartis, Amgen
<b>Verma</b>	Amol	Grant funding from not-for-profit organizations: Canadian Cancer Society, the Canadian Frailty Network, the Canadian Institutes of Health Research, the Canadian Medical Protective Agency, the Digital Research Alliance of Canada, Green Shield Canada Foundation, the Natural Sciences and Engineering Research Council of Canada, Ontario Health, the St. Michael's Hospital Association Innovation Fund, the University of Toronto Department of Medicine, and the Vector Institute Potential to acquire minority interests in the future, for co-inventing AI tool: Signal1
<b>Viau-Lapointe</b>	Julien	Speaker honoraria or lodging coverage: North American Society of Obstetric Medicine, Groupe d'Études en Médecine Obstétricale du Québec, Fédération des Pharmaciens du Québec Research funding: CIHR
<b>Villeneuve</b>	Josée	No conflicts to declare
<b>Weber</b>	Florence	No conflicts to declare
<b>Weber</b>	Florence	No conflicts to declare
<b>Yamamoto</b>	Jennifer	Speaker honoraria: Diabetes Canada, Canadian Society of Endocrinology and Metabolism, American Diabetes Association Funded grants and clinical trials: Diabetes Canada, CIHR, Health Sciences Centre Foundation; University of Calgary; University of Manitoba I have received devices free of cost or at a reduced cost for clinical trials/studies from: Abbott, Medtronic  <b><i>This speaker intends to make therapeutic recommendations for medications that have not received regulatory approval and use trade names for diabetes devices.</i></b>
<b>Yamga</b>	Eric	Consultant: Pathway MD
<b>Zipursky</b>	Jonathan	Payments for expert medicolegal opinions on the safety and effectiveness of drugs from private law firms

At September 14, 2023